WuXi AppTec
2021 Annual Results
March 24, 2022
Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Non-IFRS Financial Measures

We provide Non-IFRS gross profit and Non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations and goodwill impairment. We also provide adjusted Non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. We further provide EBITDA and adjusted EBITDA. Neither of above is required by, or presented in accordance with IFRS. Meanwhile, to better reflect the operation results and key performance, the Company has adjusted the scope of the foreign exchange-related gains or losses by excluding only the gains or losses that we believe irrelevant to the core business. The comparative financial figures for the comparable periods have been adjusted to reflect the change of the scope.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such Non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted Non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Disclaimer

All intellectual property rights and other rights pertaining to the information and materials presented in the results briefing are owned by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”). Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited. This briefing does not intend to provide a complete statement of the relevant matters. For relevant information, please refer to the Positive Profit Alert published on the website of Hong Kong Stock Exchange (www.hkexnews.hk).
All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or "IFRSs"). The unit of currency is RMB.
1. Results Overview
Strong Revenue & Profit Growth in 2021

<table>
<thead>
<tr>
<th></th>
<th>Revenue</th>
<th>Adjusted Non-IFRS Net Profit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RMB billion</td>
<td>RMB billion</td>
</tr>
<tr>
<td>2020</td>
<td>16.54</td>
<td>3.64</td>
</tr>
<tr>
<td>2021</td>
<td>22.90</td>
<td>5.13</td>
</tr>
<tr>
<td></td>
<td>+38.5%</td>
<td>+41.1%</td>
</tr>
</tbody>
</table>

**Net Profit**

<table>
<thead>
<tr>
<th></th>
<th>Net Profit</th>
<th>Net Profit After Deducting Non-Recurring Items</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RMB billion</td>
<td>RMB billion</td>
</tr>
<tr>
<td>2020</td>
<td>2.96</td>
<td>2.39</td>
</tr>
<tr>
<td>2021</td>
<td>5.10</td>
<td>4.06</td>
</tr>
<tr>
<td></td>
<td>+72.2%</td>
<td>+70.4%</td>
</tr>
</tbody>
</table>
Consistent Revenue Growth Quarter after Quarter

Consistent revenue growth every quarter except 2020Q1, due to the COVID-19 pandemic

RMB billion

2018Q1: 2.1 +21.2%
2018Q2: 2.3 +19.5%
2018Q3: 2.5 +24.8%
2018Q4: 2.7 +29.0%
2019Q1: 2.8 +29.3%
2019Q2: 3.1 +37.8%
2019Q3: 3.4 +34.7%
2019Q4: 3.6 +33.5%
2020Q1: 3.2 +15.1%
2020Q2: 4.0 +29.4%
2020Q3: 4.6 +35.4%
2020Q4: 4.7 +31.4%
2021Q1: 5.0 +55.3%
2021Q2: 5.6 +38.1%
2021Q3: 6.0 +30.6%
2021Q4: 6.4 +35.2%
Accelerating Growth on Back of CRDMO/CTDMO Business Model

Follow the Molecule – Follow the Customer – Follow the Science / Technology

Strong momentum to continue in 2022

2011-2015 CAGR: ~17%

2015-2018 CAGR: ~25%

2018-2021 CAGR: ~34%

Note: Core WuXi AppTec segments only. Does not include other revenues/eliminations and revenues from discontinued segments.
2021 Business Highlights

**Small Molecule CRDMO**
- 732 New Molecules
- 1,666 Molecules;
- 42 Commercial; 49 Phase III

**Cell & Gene Therapies CTDMO**
- 58 Pre-clinical & Phase I
- 5 Phase II, 11 Phase III

**“Long-Tail” Strategy**
- 1,660+ New Customers
- 5,700+ Active Customers

**Loyal Customer Base**
- 100% Retention of Our Top 10 Customers

**Global Footprint**
- 31 Global Sites & Branch Offices
- 34,912 Total Employees
- 32,165 Scientists & Technicians

**Success Based Projects**
- 26 INDs; 23 CTAs

**Cumulatively**
- 144 INDs; 110 CTAs

**Clinical Development**
- 1 NDA, 3 Phase III
- 14 Phase II, 74 Phase I
Our Platform & Business Model Continued to Perform Well

**Strong, Loyal & Expanding Customer Base**

- **Revenue composition**
  - Existing clients contributed **21,295M, 29%↑**
  - Newly added clients contributed **1,608M**

**Execute Long-Tail Strategy & Increase Support to Large Pharma**

- **Revenue composition**
  - Top 20 Global Pharma clients **6,733M, 24%↑**
  - All other clients **16,170M, 46%↑**

**Increase Customer Conversion to Sustain Growth**

- **Revenue composition**
  - Clients using multiple services **19,639M, 37%↑**
  - Clients using single services, 14.3%
  - Clients using multiple services, 85.7%
Strong Revenue Growth from Customers Across All the Regions

<table>
<thead>
<tr>
<th>Region</th>
<th>Revenue (bn)</th>
<th>Growth (%)</th>
<th>Revenue Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>12.15</td>
<td>+37%</td>
<td>53%</td>
</tr>
<tr>
<td>Europe</td>
<td>3.72</td>
<td>+40%</td>
<td>16%</td>
</tr>
<tr>
<td>China</td>
<td>5.80</td>
<td>+40%</td>
<td>25%</td>
</tr>
<tr>
<td>Japan, Korea &amp; Others</td>
<td>1.23</td>
<td>+41%</td>
<td>6%</td>
</tr>
</tbody>
</table>

Revenue breakdown:

- US: 53%
- Europe: 16%
- China: 25%
- Others: 6%
Continue to Attract, Train and Retain Talent to Support Rapid Growth

Professional Team with 35%+ Master or PhD

Total Employees ending Dec 31 2021
34,912

Overseas Employees
2,050

Research Employees
28,841

Manufacturing Employees
3,324

Rapid Expansion of Talent Base

2017-2021 CAGR: +24%

2017-2021 Revenue CAGR: +31%
ESG Recognition and Target by 2030

MSCI ESG Ratings in 2021: AA
The first company with AA ratings among all A-share listed companies in healthcare industry

Member of Dow Jones Sustainability Indices (2021)

Top Rated in Sustainalytics (2021)

Target by 2030 as compared to 2020
- 25% Carbon Emission Intensity
- 25% Energy Consumption Intensity
- 30% Water Use Intensity
2. Business Highlights
WuXi Chemistry: grew 47% in 2021, target double the growth in 2022

Financial Performance
- Revenue growth of **46.9%** YoY to **14.09bn**. Adjusted Non-IFRS gross profit grew by **38.0%** YoY to **5.75bn**.
- Adjusted Non-IFRS gross profit margin is **40.8%**.
- We expect revenue growth rate of WuXi Chemistry in 2022 will nearly double compared with that in 2021.

Drug Discovery (R)
- Revenue of small molecule discovery service grew **43.2%** YoY to **6.17bn**.
- Delivered 310,000+ synthesized compounds to our clients
- Revenue from "long-tail" customers in small molecule discovery service continued to have greater contribution growing **71%**.

Development and Manufacturing (D&M)
- Revenue of small molecule CDMO service grew **49.9%** YoY to **7.92bn**.
- Total pipeline of 1,666 molecules, including 42 commercial (14 new commercial projects in 2021), 49 Phase III, 257 Phase II, 1,318 Phase I and pre-clinical projects.
- Oligo & peptide D&M clients and molecules grew 128% and 154%, D&M revenue first reaching USD115 million.

Capacity Expansion
- Started to operate sites of Changzhou (Phase 2), Taixing and WuXi city (oral & sterile filling DP plants). Completed construction of Changshu site, and made milestone progress in Changzhou (Phase 3), Taixing (Phase 1) and Delaware, US.
- Completed acquisition of a DP manufacturing facility in Couvet, Switzerland from BMS.
WuXi Chemistry: Growing CRDMO Pipeline with 14 Newly Added Commercial Projects

New Molecules Entered into CDMO Funnel
Total 732

Win the Molecule
691
39
2

310,000+ compounds Individually synthesized 2021.1 – 2021.12

1,318 Preclinical & Phase I
257 Phase II
49 Phase III
42 Commercial

“R”
“D”
“M”
WuXi Chemistry: Strong Growth of CRDMO Services for New Modalities

**Revenue from Oligo and Peptide D&M**

<table>
<thead>
<tr>
<th>Year</th>
<th>USD million</th>
<th>+145%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>115</td>
<td></td>
</tr>
</tbody>
</table>

- Revenue from Oligo & Peptide D&M reached USD100m in 2021
- Expect even faster growth in 2022

**Number of Clients of Oligo and Peptide D&M**

<table>
<thead>
<tr>
<th>Year</th>
<th>+128%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>25</td>
</tr>
<tr>
<td>2021</td>
<td>57</td>
</tr>
</tbody>
</table>

- Expand capacities in oligo & peptide PD and manufacturing
- Strengthen funnel flow from lab research to process development and manufacturing; Keep sourcing long-tail customers

**Number of Molecules of Oligo & Peptide D&M**

<table>
<thead>
<tr>
<th>Year</th>
<th>+154%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>39</td>
</tr>
<tr>
<td>2021</td>
<td>99</td>
</tr>
</tbody>
</table>

- Form strategic collaboration with industry leaders in oligo & peptide
- Strengthen partnership with key suppliers to ensure stable services
Shanghai Waigaoqiao (WGQ) site passed the first drug product (DP) pre-approval inspection (PAI) by US FDA in Oct 2021.

During the same week in Oct 2021, WGQ site passed 2 DP PAIs by China NMPA.

Three successful drug product PAIs during one week is testimony to WuXi STA’s robust quality system.

- STA passed 40+ inspections by all major regulatory agencies including US FDA, EU EMA, China NMPA and Japan PMDA.
- WuXi STA has 4 DP commercial projects.
- 8 more DP projects are in Phase 3 or NDA review stage.
WuXi Chemistry: Global CDMO Footprint and Capacity Expansion

San Diego, US
API D&M
DP M
2,700m²

Couvet, Switzerland
DP M
19,000m²

Shanghai WQG
API D
DP D&M
68,800m²

Shanghai Jinshan
API & Intermediates D&M
78,500m²

Changzhou
API D&M
Oligo & Peptide D&M
215,500m²

Wuxi
DP D&M
34,200m²

Changshu
API D&M
91,800m²

Taixing
API D&M
Construction in progress
Target operation from H2-2022

Delaware, US
API D&M
DP D&M
Construction in progress
Target operation from 2025

D: development, M: manufacturing
**Financial Performance**
- Revenue growth of **38.0%** YoY to **4.53bn**. Robust growth in lab testing services and strengthened funnel flow from pre-clinical to clinical CRO.
- Adjusted Non-IFRS GP growth **36.8%** YoY to **1.53bn**.
- Adjusted Non-IFRS GPM **33.8%**

**Lab Testing Services**
- Revenue from lab testing services grew **38.9%** YoY to **3.05bn**, revenue excluding medical devices grew **52%** YoY.
- Toxicology services revenue grew **63%** YoY. We are the industry leader for drug safety evaluation services in APAC.

**Clinical CRO**
- Revenue of clinical CRO and SMO grew **36.2%** YoY to **1.48bn**.
- Provided services to around **240** projects for our clients, enabling **19** IND approvals and **12** BLA/NDA applications.

**SMO**
- SMO maintained #1 leadership position in China, with over **4,500** staffs in **155** cities and provide services in more than **1,000** hospitals.
- Team expanded **36%** YoY
- Supported **25** products approvals in 2021 vs **17** products in all of 2020.
Lab Testing Services Growth Drivers & Highlights

Growing Capacity
- New capacity of 15,000 m² lab space in Chengdu and Nanjing delivered in 2021
- 55,000 m² lab and animal facilities under construction for mid 2023 delivery

Strong Momentum
- Lab testing business backlog growth maintained strong momentum
- WIND signed 149 projects in 2021, up 49% from 100 projects in 2020

Robust Supply Chain
- Animal resource and supply ready and aligned with contract signing and study scheduling processes

HIGHLIGHTS
- Implemented in-house developed digital smart resource scheduling that reduced toxicology study scheduling from 2-3 hours to less than 30 seconds
- DMPK new modality related revenue grew 150%
- Bioanalytical Service (BAS) enabled over 500 customers and the approval of 10 new drugs and biosimilars in China
- Medical Device business released an improved customer portal (WOS 3.0) to enhance customer experience
Clinical CRO and SMO businesses leverage the strength of testing platform

1. **Drive Conversion**
   - Leverage Preclinical Opportunities

2. **Drive Conversion**
   - Capture Clinical Wins

### OPERATION COLLABORATION

#### CRO
- Establish global clinical study capability in **China, US and Australia**
- Statistics and programming business in China delivered strong growth through global FSP team collaboration
- 12 ADC projects reached key milestones
- 850+ staff across the globe
- 900+ project experience
- 50+ NDAs

#### SMO
- 10,000+ site departments and investigators
- 110,000+ patients in management
- ~2000 project experience, supported
- 81 new drugs/medical devices approved on China/EMA/FDA market in recent 7 years.
- 4500+ staff
- 155 cities, 1000 hospitals in China

---

<table>
<thead>
<tr>
<th>Follow up</th>
<th>RFI RFP</th>
<th>WIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>16</td>
<td>23</td>
</tr>
</tbody>
</table>

---

21
Financial Performance

- Revenue growth of **30.0% YoY** to **1.99bn**. Robust growth in new modalities and large molecules.
- Adjusted Non-IFRS GP growth **19.0% YoY** to **0.83bn**.
- Adjusted Non-IFRS **GPM 41.7%**

Discovery Biology

- We have the largest discovery biology enabling platform with over **2,200** experienced scientists.
- Established **3 Center of Excellence (COE)** for NASH, antiviral, neuroscience and aging.
- Strong growth from both **cancer discovery** service and **rare & immune disease** service.

New Modalities

- We continue to build new biology capabilities related to new modalities, including oligo, cancer vaccine, PROTAC, viral vector, drug delivery vehicle.
- Revenue from new modalities and large molecules in WuXi Biology grew **75%**, and its revenue contribution rose to **14.6%** in 2021, from **10.4%** in 2020.

DNA Encoded Library

- We have a leading DNA Encoded Library (DEL) with over **90** billion compounds, **6,000** proprietary scaffolds and **35,000** building blocks, **1000+** clients.
- DEL revenue grew **42%** YoY
- Through comprehensive integration of our DEL, protein production and structure-based drug design capabilities, we have established a competitive **Target-to-Hit platform**

### Financial Performance

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (RMB billion)</th>
<th>Adjusted Non-IFRS Gross Profit (RMB billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>1.53</td>
<td>0.69</td>
</tr>
<tr>
<td>2021</td>
<td>1.99</td>
<td>0.83</td>
</tr>
</tbody>
</table>
WuXi Biology Capability Building in New Modalities

+75% YOY

14.6% of total revenue in 2021 (10.4% in 2020)

In-vitro/In-vivo Biology Research Service for New Modalities

- Oligo Platform
- PROTAC®
- Vector Platform
- Cancer Vaccine
- Cell/Gene Therapy
- Novel Drug Delivery Vehicle
A Global Leader in DNA Encoded Library (DEL)

- **Largest** global customer base with over 1,000 clients
- **Pioneer DEL Kit** business model with 4th Generation DEL Kit newly launched
- **Unique** WuXi library with drug like scaffolds
- 32 patent applications, 8 granted
- 12 published academic papers
- **World renowned** academic advisors
- **Strong synergy** with WuXi Chemistry capabilities

WuXi DNA Encoded Libraries

+42% DEL Revenue in 2021

4th Generation of DEL Kit

DEL Like Never Before

- >90B compounds
- >200 libraries
- 6,000 proprietary scaffolds
- 35,000 building blocks
WuXi ATU: to see turning point in 2022, target growth quicker than industry

Financial Performance

- Revenue declined 2.8% to 1.03bn. Decline largely due to the pandemic impacting the region and BLA filing delay by cell therapy clients. ATU China grew 87%, partly offset the decline in US.
- Adjusted Non-IFRS gross profit 0.01bn.
- Adjusted Non-IFRS GPM 1.1%.

Projects

- We focused on improving our CTDMO integrated enabling platform and provided development and manufacturing services for 58 pre-clinical and Phase I projects, 5 Phase II projects, 11 Phase III projects.

Capabilities

- Backlog and revenue show sign of recovery in the U.S..
- Increased manufacturing efficiency and utilization rate, to ensure the timely delivery.
- Enhanced technical process of plasmid, LVV and AAV, further lowering the viral-vector cost of manufacturing and increasing our competitiveness.

Capacities

- Shanghai Lin-gang site opened in Oct 2021. It has 15,300 square meters, offering integrated development, manufacturing, and testing services for global clients.
- 13,000 square meters new testing facility in Philadelphia opened in Nov 2021 which tripled our testing capacity.
WuXi ATU: Growing Pipeline on Our Integrated CTDMO Platform

Cell Therapies
- CAR-T
- TIL
- Stem Cells

Gene Therapies
- AAV
- LENTI
- TESSA
- OV

US | EU | CN

Phase I: 58 projects
- 34 in US
- 24 in CN

Phase II: 5 projects
- 5 in US

Phase III: 11 projects
- 9 in US
- 2 in CN

Testing

Provided Globally Integrated CRTDMO Services to Cell & Gene Therapy product development

4 projects are in BLA preparation stage
WuXi ATU: Expanding Capacities Globally

New Facility in Philadelphia, Tripling Testing Capacity

- 13,000 square meters facility in Philadelphia opened in Nov 2021
- Triples current testing capacity for cell and gene therapy
- Supported 1,700+ customer submissions for biosafety testing
- Full testing capabilities covering assay development, biologics safety testing, viral clearance, commercial lot release assays

New Facility in Shanghai to Serve Global Clients

- Integrated CTDMO site in Shanghai Lin-gang opened in Oct 2021
- 15,300 square meters facility contains 200+ independent suites and 6 complete production lines
- Offers integrated development, manufacturing, and testing services for viral vectors and cell therapies to global clients
WuXi DDSU: enabling China-based customer innovation, business to evolve in 2022

Financial Performance

- Revenue growth of 17.5% YoY to 1.25bn.
- Adjusted Non-IFRS GP growth 9.3% YoY to 0.57bn.
- Adjusted Non-IFRS GPM 45.6%.

Project Number

- During the Reporting Period, our success-based drug discovery service unit filed INDs for 26 drug candidates and obtained 23 CTAs.
- Cumulatively submitted 144 new chemical entity IND filings and obtained 110 CTAs, with 1 project in NDA review stage, 3 project in Phase III clinical trial, 14 projects in Phase II clinical trials, and 74 projects in Phase I clinical trials.

Innovative R&D

- Among the 144 projects that INDs were filed or currently in clinical stage, ~70% of the projects rank top 3 in China, in terms of their drug development progress among same-class drug candidates.

Sales Royalties

- On July 24 2021, our partner submitted the first NDA filing for the drug discovered by our DDSU.
- Upon the products’ successful launch to the market by our customers, we would begin receiving sales royalty income.
WuXi DDSU: Success-based Business Model with Potential Upside

144 IND filings\(^2\)

\(~70\%\) Top 3 in China\(^1\)

<table>
<thead>
<tr>
<th>232 ongoing projects ended December 31, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug discovery &amp; pre-clinical: 100</td>
</tr>
<tr>
<td>IND &amp; beyond: 132</td>
</tr>
<tr>
<td>IND: 34</td>
</tr>
<tr>
<td>Clinical: 98</td>
</tr>
<tr>
<td>CTA: 6</td>
</tr>
<tr>
<td>P1: 74</td>
</tr>
<tr>
<td>P2: 14</td>
</tr>
<tr>
<td>P3: 3</td>
</tr>
<tr>
<td>NDA: 1</td>
</tr>
</tbody>
</table>

Note:
1. Rank by clinical development speed among same-class drug candidates
2. 12 projects in CTA, Phase 1 and Phase 2 stages were stopped clinical development by clients so far
3. Financial Performance
Note: The Company has adjusted the scope of the foreign exchange related gains or losses in the calculation of non-IFRS measures since June 2021, by adjusting only the gains or losses that the management believes are irrelevant to the core business. The comparative financial figures for the comparable periods has been adjusted to reflect the change of scope.
Segment Revenue

**WuXi Chemistry**
- 2020: 9,588
- 2021: 14,087
- Growth: +46.9%

**WuXi Testing**
- 2020: 3,278
- 2021: 4,525
- Growth: +38.0%

**WuXi Biology**
- 2020: 1,526
- 2021: 1,985
- Growth: +30.0%

**WuXi ATU**
- 2020: 1,056
- 2021: 1,026
- Growth: -2.8%

**WuXi DDSU**
- 2020: 1,065
- 2021: 1,251
- Growth: +17.5%
Segment Non-IFRS Gross Profit

RMB MM

WuXi Chemistry

2020: 4,167
2021: 5,751
Adjusted Non-IFRS Gross Margin: 43.5% → 40.8%
Change: +38.0%

WuXi Testing

2020: 1,118
2021: 1,530
Adjusted Non-IFRS Gross Margin: 34.1% → 33.8%
Change: +36.8%

WuXi Biology

2020: 695
2021: 827
Adjusted Non-IFRS Gross Margin: 45.5% → 41.7%
Change: +19.0%

WuXi ATU

2020: 155
2021: 11
Adjusted Non-IFRS Gross Margin: 14.7% → 1.1%
Change: -92.7%

WuXi DDSU

2020: 522
2021: 571
Adjusted Non-IFRS Gross Margin: 49.0% → 45.6%
Change: +9.3%
### Revenue and Adjusted Non-IFRS Gross Profit at Constant Exchange Rate (CER)

<table>
<thead>
<tr>
<th></th>
<th>FY2021 (RMB Million)</th>
<th>FY2020 (RMB Million)</th>
<th>YoY</th>
<th>FY2021 ex. Hedge @CER</th>
<th>FY2020 ex. Hedge</th>
<th>YoY@CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>22,902</td>
<td>16,535</td>
<td>38.5%</td>
<td>23,157</td>
<td>16,467</td>
<td>40.6%</td>
</tr>
<tr>
<td>Adjusted Non-IFRS Gross Profit</td>
<td>8,704</td>
<td>6,670</td>
<td>30.5%</td>
<td>8,842</td>
<td>6,584</td>
<td>34.3%</td>
</tr>
<tr>
<td>Adjusted Non-IFRS Gross Profit Margin</td>
<td>38.0%</td>
<td>40.3%</td>
<td>-2.3pts</td>
<td>38.2%</td>
<td>40.0%</td>
<td>-1.8pts</td>
</tr>
</tbody>
</table>

The Company implemented effective hedging program for 2021 that largely mitigated the unfavorable foreign exchange impact.

**Note:** In 2021, approximately 75% of our revenues were denominated in currencies other than RMB. Because our financial statements are reported in RMB, changes in foreign currency exchange rates can significantly affect our financial results. As a result, we believe that reporting results of revenue and gross profit margin that exclude the effects of foreign currency rate fluctuations can facilitate analysis of period to period comparisons. This constant currency information excludes hedge impact, and assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results.
## IFRS & Adjusted Non-IFRS Measures

<table>
<thead>
<tr>
<th></th>
<th>FY2021</th>
<th>FY2020</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>22,902</td>
<td>16,535</td>
<td>38.5%</td>
</tr>
<tr>
<td><strong>IFRS Gross Margin%</strong></td>
<td>36.1%</td>
<td>37.8%</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS Gross Margin%</strong></td>
<td>38.0%</td>
<td>40.3%</td>
<td></td>
</tr>
<tr>
<td><strong>IFRS Operating Profit</strong></td>
<td>6,261</td>
<td>3,656</td>
<td>71.3%</td>
</tr>
<tr>
<td><strong>IFRS Operating Profit Margin%</strong></td>
<td>27.3%</td>
<td>22.1%</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS Operating Profit</strong></td>
<td>6,181</td>
<td>4,439</td>
<td>39.3%</td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS Operating Profit Margin%</strong></td>
<td>27.0%</td>
<td>26.8%</td>
<td></td>
</tr>
<tr>
<td><strong>Net Profit Attributable to Owners of the Company</strong></td>
<td>5,097</td>
<td>2,960</td>
<td>72.2%</td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS Net Profit Attributable to Owners of the Company</strong></td>
<td>5,131</td>
<td>3,637</td>
<td>41.1%</td>
</tr>
<tr>
<td><strong>IFRS EPS (RMB)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Basic</td>
<td>1.75</td>
<td>1.06</td>
<td>65.1%</td>
</tr>
<tr>
<td>-Diluted</td>
<td>1.73</td>
<td>1.05</td>
<td>64.8%</td>
</tr>
<tr>
<td><strong>Adjusted Non-IFRS EPS(RMB)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Basic</td>
<td>1.76</td>
<td>1.30</td>
<td>35.4%</td>
</tr>
<tr>
<td>-Diluted</td>
<td>1.75</td>
<td>1.29</td>
<td>35.7%</td>
</tr>
<tr>
<td><strong>Weighted Average Number of Shares’000</strong></td>
<td>2,914,820</td>
<td>2,793,408</td>
<td></td>
</tr>
<tr>
<td><strong>Fully Diluted Weighted Average Number of Shares’000</strong></td>
<td>2,937,717</td>
<td>2,818,348</td>
<td></td>
</tr>
</tbody>
</table>

*Note:* “IFRS Operating Profit” is calculated based on IFRS Gross Profit deducted by SG&A, R&D expenses and impairment losses while adding Other income and Other gains and losses, which aligns with the disclosure in Group Consolidated Profit & Loss Statement.
Adjusted Non-IFRS Net Profit

<table>
<thead>
<tr>
<th></th>
<th>FY2021</th>
<th>FY2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Profit Attributable to the owners of the Company</strong></td>
<td>5,097</td>
<td>2,960</td>
</tr>
<tr>
<td>Add:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share-based compensation expenses</td>
<td>540</td>
<td>588</td>
</tr>
<tr>
<td>Issuance expenses of Convertible Bonds</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Fair value losses from derivative component of Convertible Bonds</td>
<td>1,001</td>
<td>1,349</td>
</tr>
<tr>
<td>Foreign exchange related losses</td>
<td>113</td>
<td>358</td>
</tr>
<tr>
<td>Amortization of acquired intangible assets from merge and acquisition</td>
<td>56</td>
<td>36</td>
</tr>
<tr>
<td>Goodwill impairment</td>
<td>-</td>
<td>44</td>
</tr>
<tr>
<td><strong>Non-IFRS Net Profit Attributable the owners of the Company</strong></td>
<td>6,810</td>
<td>5,340</td>
</tr>
<tr>
<td>Add:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Realized and unrealized gains from venture investments</td>
<td>(1,475)</td>
<td>(1,717)</td>
</tr>
<tr>
<td>Realized and unrealized share of losses from joint ventures</td>
<td>25</td>
<td>14</td>
</tr>
<tr>
<td>Net disposal gain on sale of assets/business</td>
<td>(229)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Adjusted non-IFRS net profit attributable to the owners of the Company</strong></td>
<td>5,131</td>
<td>3,637</td>
</tr>
</tbody>
</table>
Capital Expenditure and Total Debt

**Capital Expenditure**

1. Capital expenditure includes purchase of property, plant and equipment, other intangible assets, prepaid lease payments and other long-term expenses.

**Total Borrowings**

2. Total borrowings include short-term and long-term borrowings, excluding the lease liabilities and convertible bond issued in Q3'2019.

**Note:**

1. Capital expenditure includes purchase of property, plant and equipment, other intangible assets, prepaid lease payments and other long-term expenses.

2. Total borrowings include short-term and long-term borrowings, excluding the lease liabilities and convertible bond issued in Q3'2019.
4. Growth Outlook
2022 Outlook

1. We expect strong **revenue growth** of 65-70% YoY in 2022
   - WuXi Chemistry expects revenue to nearly double
   - WuXi Testing and WuXi Biology to continue the growth trajectory in the past few years
   - WuXi ATU expects to see a revenue growth above industry average
   - WuXi DDSU focuses on business evolution with a slight revenue drop

2. We expect to keep the expansive pace of **Capex** in 2022, to be RMB 9-10bn
   - Accelerate manufacturing sites build-up including Taixing (Phase 1), Changzhou (Phase 3) and US Delaware
   - Accelerate research sites build-up including Nantong, Tianjin, Chengdu, Suzhou
   - Accelerate globalization, offering services from global sites to our clients

3. Strong balance sheet and ample credit facility give us flexibility to fund our Capex

Disclaimer: This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect.